Based on the findings of the present study and published data, a working model is presented in Figure 7, proposing that the OKA treatment leads to (1) cognitive impairment/AD-like pathology by inducing (2) tau phosphorylation and NFTs, (3) neuroinflammation, (4) mitochondrial dysfunction, and (5) apoptosis. The gene discussed is MAPT; the disease is Alzheimer disease.